Resources from the same session
6093 - BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy. SCAT Trial
Presenter: Bartomeu Massuti
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5626 - JIPANG study: Randomized Phase III Study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status
Presenter: Masahiro Tsuboi
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1522 - A Comprehensive Model of Genetic-Features Predicts Outcome of Personalized Adjuvant Treatment in Resected EGFR-mutant Stage II-IIIA NSCLC: Results from a Phase 3 Trial (CTONG 1104-ADJUVANT)
Presenter: Yi-Long Wu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2782 - Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC – Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial.
Presenter: Solange Peters
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1634 - Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: 10-year follow-up of West Japan Thoracic Oncology Group WJTOG0105
Presenter: Yoshitaka Zenke
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
4480 - Efficacy of durvalumab in patients with Stage III NSCLC who experience pneumonitis (PACIFIC)
Presenter: Johan Vansteenkiste
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1920 - Differential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma
Presenter: Shaorong Yu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3721 - Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: long-term survival and toxicity analysis
Presenter: Ikuo Sekine
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5386 - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy plus atezolizumab
Presenter: Davey Daniel
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant 1439PD, 1440PD and 1441PD
Presenter: Virginie Westeel
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast